Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

April 1, 2007

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 16 No 4

Volume 16

Issue 4

Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

TOKYO, JapanEisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.

Articles in this issue

Curcumin Evaluated for the Treatment of Pancreatic Cancer

Tykerb Approved for Metastatic HER2+ Breast Cancer

'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients

Drug for BPH May Also Reduce the Risk of Prostate Cancer

Phase III Trial of Prostvac-VF Is Launched

Electronic System Reminds Patients to Schedule Exams

Phase II Trial of Panzem for Renal Cell Carcinoma Initiated

Chemotherapy May Enrich Tumorigenic Cells in Breast Ca

Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway

Watchful Waiting Management for Prostate Ca a Hard Sell

Once-Weekly SC Idraparinux Equals Standard DVT Rx

Patients Using Unapproved Cancer Agent

CT Lung Screens: No Lives Saved

Transgene Enrolls First Patients in Trial of TG 1042 in CBCL

FDA Updates Warning Labels of ESAs in Cancer Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.

Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.

Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.

Related Content

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Leslie Elmore;Neil Carleton;Michael S. Cowher;Rohit Bhargava;Emilia Diego;Kristin Lupinacci;Meaghan Marley;Qurat Ul Ain Sabih;Atilla Soran, MD, MPH;Jennifer Steiman;Ronald Johnson;Erin Bayley;Priscilla F. Mcauliffe, MD, PhD

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Daratumumab Combo Prolonged Efficacy in Asian Patients with Multiple Myeloma

Roman Fabbricatore

The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Maria de la Torre;Erna Busch-Devereaux;Joyce Au

Related Content

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Leslie Elmore;Neil Carleton;Michael S. Cowher;Rohit Bhargava;Emilia Diego;Kristin Lupinacci;Meaghan Marley;Qurat Ul Ain Sabih;Atilla Soran, MD, MPH;Jennifer Steiman;Ronald Johnson;Erin Bayley;Priscilla F. Mcauliffe, MD, PhD

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Daratumumab Combo Prolonged Efficacy in Asian Patients with Multiple Myeloma

Roman Fabbricatore

The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Maria de la Torre;Erna Busch-Devereaux;Joyce Au

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.